Lung Cancer Research Review, Issue 5

In this Issue:

Extensive follow-up after surgery in NSCLC
Identifying ALK-positive tumours for therapy
Tremelimumab: activity in malignant mesothelioma
Erlotinib + bevacizumab maintenance therapy in NSCLC
Vandetanib may prolong PFS in NSCLC
Pemetrexed + intermittent erlotinib in recurrent NSCLC
Erlotinib ± alternating chemotherapy in relapsed NSCLC
Defining tumour growth rate during progression on EGFR-TKIs
Onartuzumab may benefit METpositive NSCLC
Opportunities to improve lung cancer management

Please login below to download this issue (PDF)